Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

NCT06265545 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT06265545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06265545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Not applicable
Overall status
Recruiting
Start date
February 22, 2024
Completion date
June 30, 2028
Enrollment
458 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml, refractory, relapsed